UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Clinical infectious diseases, 2013-06, Vol.56 (11), p.1637-1645

2013

Volltextzugriff (PDF)

Conversion of cellular sialic acid expression from N-acetyl- to N-glycolylneuraminic acid using a synthetic precursor, N-glycolylmannosamine pentaacetate: inhibition of myelin-associated glycoprotein binding to neural cells

Glycobiology (Oxford), 2000-01, Vol.10 (1), p.11-20

2000

Volltextzugriff (PDF)

Molecularly cloned mammalian glucosamine-6-phosphate deaminase localizes to transporting epithelium and lacks oscillin activity

The FASEB journal, 1998-01, Vol.12 (1), p.91-99

1998

Volltextzugriff (PDF)

Week 96 analyses of emergent drug resistance from the STaR Study: rilpivirine/emtricitabine/ tenofovir DF vs. efavirenz/emtricitabine/tenofovir DF single-tablet regimens

Antiviral therapy, 2014-01, Vol.19, p.A123-A123

2014

Volltextzugriff (PDF)

Primary and secondary analyses of emergent drug resistance through week 48 from the STaR Study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF single-tablet regimens

Antiviral therapy, 2013-01, Vol.18, p.A38-A38

2013

Volltextzugriff (PDF)

STaR study: single-tablet regimen rilpivirine/emtricitabine/tenofovir DF maintains non-inferiority to efavirenz/emtricitabine/tenofovir DF and has minimal impact on fasting lipids in ART-naive adults through week 96

Antiviral therapy, 2013-01, Vol.18, p.A7-A7

2013

Volltextzugriff (PDF)

STAR: Rilpivirine/Emtricitabine/TenofovirDF is non-inferior to Efavirenz/Emtricitabine/TenofovirDF in naive adult Latino, black & white subpopulations

Journal of the International AIDS Society, 2013-06, Vol.16 (Suppl 1)

2013

Volltextzugriff (PDF)

Efficacy of switching to rilpivirine/emtricitabine/tenofovir DF from boosted PI in HIV-1 virologically suppressed patients with or without the K103N

Journal of the International AIDS Society, 2013-06, Vol.16 (Suppl 1)

2013

Volltextzugriff (PDF)

SPIRIT: switching to emtricitabine/rilpivirine/tenofovir DF single‐tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48

Journal of the International AIDS Society, 2012-11, Vol.15 (S4), p.1-1

2012

Volltextzugriff (PDF)

STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non‐inferior to efavirenz/emtricitabine/tenofovir DF in ART‐naïve adults

Journal of the International AIDS Society, 2012-11, Vol.15 (S4), p.1-1

2012

Volltextzugriff (PDF)

Variations in Outcomes of Care in Urban and Rural Nursing Facilities in Maine

Journal of applied gerontology, 1996-06, Vol.15 (2), p.202-223

1996

Volltextzugriff (PDF)

Linked Data Analysis of Dually Eligible Beneficiaries in New England

Health care financing review, 1998, Vol.20 (2), p.91-108

1998

Volltextzugriff (PDF)

Variations in outcomes of care in urban and rural nursing facilities in Maine : Rural nursing homes

Journal of applied gerontology, 1996, Vol.15 (2), p.202-223

1996

Volltextzugriff (PDF)

Forged at Workforce Entry? CEO Imprinting, Information Uncertainty and Merger Wave Timing

Journal of management studies, 2023-10

2023

Volltextzugriff (PDF)

“Invincibles” and “invisibles”: CEO status and the ‘Matthew effect’ in strategic decision-making

Long range planning, 2020-06, Vol.53 (3), p.101887, Article 101887

2020

Volltextzugriff (PDF)

The financial crisis, acquisition premiums and the moderating effect of CEO power

Long range planning, 2018-04, Vol.51 (2), p.204-218

2018

Volltextzugriff (PDF)

The impact of target CEO celebrity on M&A premiums

Canadian journal of administrative sciences, 2020-09, Vol.37 (3), p.268-282

2020

Volltextzugriff (PDF)

Legislative political connections and CEO compensation in China

Asian business & management, 2018-04, Vol.17 (2), p.112-139

2018

Volltextzugriff (PDF)

Bet-the-company decisions: when do they pay off?

The Journal of Business Strategy, 2016-01, Vol.37 (1), p.44-50

Fralich, Russell

2016

Volltextzugriff (PDF)

Shaping the Health and Long-Term-Care Infrastructure Serving Older Adults: Historical Trends and Future Directions

Maine policy review, 2015-12, Vol.24 (2)

Fralich, Julie

2015

Volltextzugriff (PDF)

Zoom Communication Inc.: keeping the good times going?

The Case journal, 2023-11, Vol.19 (6), p.800-824

2023

Volltextzugriff (PDF)

CEO social capital and contingency pay: a test of two perspectives

Corporate governance (Bradford), 2015-08, Vol.15 (4), p.476-490

2015

Volltextzugriff (PDF)

Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for subsequent therapy

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.166-166

2024

Volltextzugriff (PDF)

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

AIDS (London), 2014-04, Vol.28 (7), p.989-997

2014

Volltextzugriff (PDF)

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

AIDS (London), 2014-01, Vol.28 (3), p.335-344

2014

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(80)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Conversion of cellular sialic acid expression from N-acetyl- to N-glycolylneuraminic acid using a synthetic precursor, N-glycolylmannosamine pentaacetate: inhibition of myelin-associated glycoprotein binding to neural cells

Molecularly cloned mammalian glucosamine-6-phosphate deaminase localizes to transporting epithelium and lacks oscillin activity

Week 96 analyses of emergent drug resistance from the STaR Study: rilpivirine/emtricitabine/ tenofovir DF vs. efavirenz/emtricitabine/tenofovir DF single-tablet regimens

Primary and secondary analyses of emergent drug resistance through week 48 from the STaR Study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF single-tablet regimens

STaR study: single-tablet regimen rilpivirine/emtricitabine/tenofovir DF maintains non-inferiority to efavirenz/emtricitabine/tenofovir DF and has minimal impact on fasting lipids in ART-naive adults through week 96

STAR: Rilpivirine/Emtricitabine/TenofovirDF is non-inferior to Efavirenz/Emtricitabine/TenofovirDF in naive adult Latino, black & white subpopulations

Efficacy of switching to rilpivirine/emtricitabine/tenofovir DF from boosted PI in HIV-1 virologically suppressed patients with or without the K103N

SPIRIT: switching to emtricitabine/rilpivirine/tenofovir DF single‐tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48

STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non‐inferior to efavirenz/emtricitabine/tenofovir DF in ART‐naïve adults

Variations in Outcomes of Care in Urban and Rural Nursing Facilities in Maine

Linked Data Analysis of Dually Eligible Beneficiaries in New England

Variations in outcomes of care in urban and rural nursing facilities in Maine : Rural nursing homes

Forged at Workforce Entry? CEO Imprinting, Information Uncertainty and Merger Wave Timing

“Invincibles” and “invisibles”: CEO status and the ‘Matthew effect’ in strategic decision-making

The financial crisis, acquisition premiums and the moderating effect of CEO power

The impact of target CEO celebrity on M&A premiums

Legislative political connections and CEO compensation in China

Bet-the-company decisions: when do they pay off?

Shaping the Health and Long-Term-Care Infrastructure Serving Older Adults: Historical Trends and Future Directions

Zoom Communication Inc.: keeping the good times going?

CEO social capital and contingency pay: a test of two perspectives

Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for subsequent therapy

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

Suchergebnisse filtern